Multimodal control of Cdc25A by nitrosative stress.
Cdc25A propels cell cycle progression, is overexpressed in numerous human cancers, and possesses oncogenic and antiapoptotic activities. Reactive oxygen species, such as hydrogen peroxide, regulate Cdc25A, but the physiologic and pathologic effects of nitric oxide (*NO) and *NO-derived reactive species are not well defined. Herein, we report novel independent mechanisms governing Cdc25A in response to nitrosative insult. We observed direct and rapid inhibition of Cdc25A phosphatase activity after in vitro treatment with the low molecular mass cell-permeable S-nitrosothiol S-nitrosocysteine ethyl ester (SNCEE). In addition, treatment of cancer cells with SNCEE induced nitrosative stress and decreased Cdc25A protein levels in a time-dependent and concentration-dependent manner. Similarly, iNOS-derived *NO was sufficient to suppress Cdc25A expression, consistent with its role in mediating nitrosative stress. Whereas a decrease in Cdc25A half-life was not observed in response to SNCEE, we found the translational regulator eukaryotic initiation factor 2alpha (eIF2alpha) was hyperphosphorylated and total protein translation was decreased with kinetics consistent with Cdc25A loss. Inhibition of eIF2alpha decreased Cdc25A levels, supporting the hypothesis that SNCEE suppressed Cdc25A translation through inhibition of eIF2alpha. Nitrosative stress decreased the Cdc25A-bound fraction of apoptosis signal-regulating kinase-1 (ASK-1) and sensitized cells to apoptosis induced by the ASK-1-activating chemotherapeutic cis-diaminedichloroplatinum (II), suggesting that nitrosative stress-induced suppression of Cdc25A primed cells for ASK-1-dependent apoptosis. Together these data reveal novel *NO-dependent enzymatic and translational mechanisms controlling Cdc25A, and implicate Cdc25A as a mediator of *NO-dependent apoptotic signaling.
Tomko
Robert J
RJ
Department of Pharmacology and Chemical Biology and University of Pittsburgh Drug Discovery Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA.
Lazo
John S
JS
D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology; D003545:Cysteine / Q000031:analogs & derivatives / Q000494:pharmacology; D015536:Down-Regulation; D015852:Eukaryotic Initiation Factor-2 / Q000037:antagonists & inhibitors / Q000378:metabolism; D045325:HCT116 Cells; D006801:Humans; D007700:Kinetics; D048848:MAP Kinase Kinase Kinase 5 / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism*; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D009603:Nitroso Compounds / Q000494:pharmacology; D010084:Oxidation-Reduction; D010766:Phosphorylation; D014176:Protein Biosynthesis; D020687:cdc25 Phosphatases / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*
D015852:Eukaryotic Initiation Factor-2; D009603:Nitroso Compounds; C429310:S-nitrosocysteine ethyl ester; D009569:Nitric Oxide; C496319:NOS2 protein, human; D052247:Nitric Oxide Synthase Type II; D048848:MAP Kinase Kinase Kinase 5; C482858:MAP3K5 protein, human; C517004:CDC25A protein, human; D020687:cdc25 Phosphatases; D003545:Cysteine; D002945:Cisplatin
Cell. 1998 May 15;93(4):617-25
9604936
Cancer Res. 2007 Apr 1;67(7):3356-63
17409445
J Med Chem. 2001 Nov 22;44(24):4042-9
11708908
J Cell Biol. 2005 Oct 10;171(1):35-45
16216921
Mol Cell Biol. 2003 Feb;23(4):1292-303
12556489
Antioxid Redox Signal. 2005 May-Jun;7(5-6):761-7
15890022
Oncogene. 2007 Mar 22;26(13):1949-53
17001315
J Biol Chem. 2006 Nov 17;281(46):34742-50
16923815
Neuron. 1997 May;18(5):691-6
9182795
Science. 2005 Feb 11;307(5711):935-9
15705855
Biochem Biophys Res Commun. 2000 Nov 11;278(1):263-7
11071882
Biochem Biophys Res Commun. 2006 Dec 29;351(4):825-30
17097061
Arch Biochem Biophys. 2003 Sep 15;417(2):194-202
12941301
Arch Biochem Biophys. 1998 Oct 15;358(2):232-42
9784235
J Biol Chem. 2002 Jun 7;277(23):20535-40
11925443
Mol Carcinog. 1996 May;16(1):20-31
8634091
Annu Rev Pharmacol Toxicol. 2005;45:725-50
15822194
Biochem Soc Trans. 2006 Feb;34(Pt 1):7-11
16246168
Free Radic Biol Med. 2006 Jan 15;40(2):247-59
16413407
Mol Pharmacol. 2007 Jan;71(1):184-92
17018577
Oncogene. 1999 Jan 7;18(1):173-80
9926932
Genes Dev. 2004 Feb 1;18(3):249-54
14871926
Nat Rev Cancer. 2007 Jul;7(7):495-507
17568790
Nature. 2005 Apr 14;434(7035):864-70
15829956
Mol Cell Biol. 1999 Jul;19(7):4819-24
10373531
Science. 2000 May 26;288(5470):1425-9
10827953
EMBO J. 1994 Sep 15;13(18):4278-90
7925273
Nature. 2006 May 25;441(7092):513-7
16724068
Mol Cell Biol. 2001 Jul;21(14):4818-28
11416155
J Am Chem Soc. 2005 Nov 16;127(45):15815-23
16277524
J Biol Chem. 1996 Aug 2;271(31):18596-603
8702510
Biochemistry. 2000 Feb 8;39(5):1040-7
10653649
Biol Chem. 2004 Jan;385(1):1-10
14977040
Nat Rev Mol Cell Biol. 2005 Feb;6(2):150-66
15688001
Cell Cycle. 2007 Aug 1;6(15):1919-26
17671423
Biochemistry. 2003 Sep 2;42(34):10060-70
12939134
Biochem J. 2001 Aug 1;357(Pt 3):593-615
11463332
Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2442-7
8637893
Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2623-9
16210571
Nature. 2001 Apr 12;410(6830):842-7
11298456
Nat Rev Mol Cell Biol. 2005 Apr;6(4):318-27
15803138
Nat Rev Drug Discov. 2002 Dec;1(12):939-50
12461516
Antioxid Redox Signal. 2005 Jul-Aug;7(7-8):930-9
15998248
J Med Chem. 2001 Jun 7;44(12):2035-8
11384248
Mol Cell. 2000 May;5(5):897-904
10882126
Trends Biochem Sci. 1995 Mar;20(3):105-8
7709427
Free Radic Biol Med. 2003 Apr 15;34(8):955-68
12684081